Phase 3 pivotal program in MESI – PEAK and PINNACLE Study Design Weeks D1 4 8 12 16 20 24 28 32 36 40 44 48 KSI-101 5 mg (n >50) KSI-101 10 mg (n >50) Sham (n >50) Primary endpoint KSI-101 5 mg injection Sham injection KSI-101 10 mg injection Individualized treatment (PRN) Sham PRN Fixed monthly dosing Individualized dosing PEAK and PINNACLE are actively enrolling 71 Rescue criteria • BCVA decrease ≥15 letters and CST worsening by ≥100 μm from Day 1, due to MESI. • Worsening of inflammation by ≥2 grade levels in anterior chamber cells and/or vitreous haze; or progression to grade 4. • The intraocular inflammation complications in the Study Eye did not improve and require rescue treatment to prevent irreversible loss of vision per Investigator’s judgment. Rescue Treatment allowed from Week 4 to Week 44, when warranted